Diagnosis, clinical characteristics, and treatment of combined hepatocellular-cholangiocarcinoma

被引:0
|
作者
Terashima, Takeshi [1 ]
Harada, Kenichi [2 ]
Yamashita, Taro [1 ]
机构
[1] Kanazawa Univ Hosp, Dept Gastroenterol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
[2] Kanazawa Univ, Dept Human Pathol, Grad Sch Med Sci, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan
关键词
combined hepatocellular-cholangiocarcinoma; systemic therapy; immunotherapy; PLATINUM-BASED CHEMOTHERAPY; CARCINOMA; FEATURES; HEPATOCHOLANGIOCARCINOMA; CT;
D O I
10.1093/jjco/hyaf029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The concept and definition of combined hepatocellular-cholangiocarcinoma (cHCC-CCA), an extremely rare condition accounting for only 1% of all primary liver cancers, has shifted in recent years. The latest World Health Organization Classification (fifth edition) includes two types of cHCC-CCAs, (i) the classical type described in the previous edition, which contains a mixture of distinctly differentiated components of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) and (ii) intermediate cell carcinoma wherein all cells comprising the tumor express both hepatocellular and cholangiocellular features. However, the pathogenesis of cHCC-CCA, including its origins, remains controversial even among experts. Treatment strategies for cHCC-CCA in clinical practice have been determined based on imaging findings, tumor markers, and pathologically predominant tumor components for either HCC or ICC, suggesting that cHCC-CCA has yet to be been established as an independent disease entity. As with HCC and ICC, the treatment strategy for HCC-CCA involves initially considering resectability. Although systemic therapy has been considered for patients unsuitable for local treatment, no prospective clinical trials have evaluated the efficacy and safety of systemic therapy for cHCC-CCA, which could explain the lack of a standard of care. In recent years, however, studies have demonstrated the efficacy of immune checkpoint inhibitors for HCC and ICC, with therapeutic results having been reported for cHCC-CCA. Hence, further accumulation of cases is expected to facilitate the establishment of a consensus on treatment strategies in the near future. The WHO Classification includes a definition for combined hepatocellular-cholangiocarcinoma. Treatment strategies are determined according to either hepatocellular carcinoma or intrahepatic cholangiocarcinoma considering tumor markers or radiological and pathological findings.
引用
收藏
页码:327 / 333
页数:7
相关论文
共 50 条
  • [31] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA: AN INDICATION FOR LIVER TRANSPLANTATION?
    Schaefer, I. -M.
    Reinecke, J. A.
    Goralczyk, A.
    Schultze, F. C.
    Amanzada, A.
    Schweyer, S.
    Lorf, T.
    Obed, A.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 39 - 39
  • [32] Carcinoma of ectopic liver tissue shares characteristics with combined hepatocellular-cholangiocarcinoma
    Geng, Shi-Kai
    Zhou, Jian-Hong
    Liu, You-Jun
    Xu, Li-Ping
    Wang, Nong-Rong
    Sun, Jian
    Chen, Nan-Ping
    Yu, Xue-Feng
    Deng, Jun
    Yin, Sheng-Jiang
    Wang, Meng-Meng
    Su, Yue
    Lu, Qi
    Qu, Qiang-Guan
    Yi, Fan
    Mei, Jin-Hong
    Feng, Qiong
    Gong, Zhi-Qiang
    Yang, Hong-Wu
    Deng, Huan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (11): : 12142 - 12153
  • [33] Clinicopathological Characteristics in Combined Hepatocellular-Cholangiocarcinoma: A Single Center Study in Korea
    Park, Hana
    Choi, Ki Hong
    Choi, Sae-Byeol
    Choi, Jong Won
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Kyung Sik
    Choi, Jin Sub
    Han, Kwang-Hyub
    Chon, Chae Yoon
    Park, Jun Yong
    YONSEI MEDICAL JOURNAL, 2011, 52 (05) : 753 - 760
  • [34] EXPRESSION OF ABH AND LEWIS BLOOD-GROUP ANTIGENS IN COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - POSSIBLE EVIDENCE FOR THE HEPATOCELLULAR ORIGIN OF COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    OKADA, Y
    JINNO, K
    MORIWAKI, S
    MORICHIKA, S
    TORIGOE, SI
    ARIMA, T
    NAGASHIMA, H
    KOPROWSKI, H
    CANCER, 1987, 60 (03) : 345 - 352
  • [35] Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki, M.
    Sato, Y.
    Nakanuma, Y.
    HISTOPATHOLOGY, 2022, 80 (05) : 859 - 868
  • [36] A HISTOCHEMICAL-STUDY ON COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA
    UEKUSA, T
    MASTUMOTO, T
    ABE, H
    FUKUDA, Y
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 1985, 18 (06) : 673 - 673
  • [37] Epigenetic regulation of combined hepatocellular-cholangiocarcinoma subtypes
    Schachtschneider, Kyle M.
    Lokken, Ryan Peter
    Huang, Yu-Hui
    Guzman, Grace
    Schook, Lawrence B.
    Gaba, Ron C.
    CANCER RESEARCH, 2019, 79 (13)
  • [38] COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA - A HISTOLOGIC AND IMMMUNOHISTOCHEMICAL STUDY
    GOODMAN, ZD
    ISHAK, KG
    LANGLOSS, JM
    SESTERHENN, IA
    RABIN, L
    CANCER, 1985, 55 (01) : 124 - 135
  • [39] EVIDENCE FOR A HEPATOCELLULAR LINEAGE IN A COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA OF TRANSITIONAL TYPE
    FISCHER, HP
    DOPPL, W
    OSBORN, M
    ALTMANNSBERGER, M
    VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1988, 56 (02) : 71 - 76
  • [40] Breast Metastasis From a Combined Hepatocellular-Cholangiocarcinoma
    Silva, Marco
    Coelho, Rosa
    Rios, Elisabete
    Gomes, Sara
    Carneiro, Fatima
    Macedo, Guilherme
    ACG CASE REPORTS JOURNAL, 2019, 6 (04)